Medical Advocates

HCV Infection/Disease
  Main Page
 
New/Noteworthy
FDA Recalls
General Reports
Pathogenesis
Virology  
Special Populations
Natural History
Screening
Risk Factors
Clinical Variants
Coinfections
Extrahepatic Manifestations  
Epidemiology/Nat'l Studies
Oncology
Diagnostics
Treatment
Drugs
Patient Perspectives
Prevention 
Vaccinations     
Links                

 

Home Page Main New/Newsworthy  Disease Index      

Last Update:  September 14, 2017
 
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy
 
     

September 2017
 
 

General Reports
 

    Journal Papers, Abstracts, and Commentaries

 

 

 

FULL-TEXT ARTICLE
Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study
Hajarizadeh B1, Grady B2, Page K3,et al 
J Viral Hepat
. 2015 Sep;22(9):708
Paper

Dual Roles of Two Isoforms of Autophagy-related Gene ATG10 in HCV-Subgenomic replicon Mediated Autophagy Flux and Innate Immunity.
Zhao Q, Hu ZY, Zhang JP, et al
Sci Rep. 2017 Sep 12;7(1):11250
Abstract

Nuclear Magnetic Resonance Study of RNA Structures at the 3'-End of the Hepatitis C Virus Genome.
Kranawetter C, Brady S, Sun L, et al
Biochemistry
. 2017 Sep 6
Abstract

Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review.
Mattingly TJ 2nd, Perfetto EM, Johnson S.
Hepatology. 2017 Aug 23.
Abstract

FULL-TEXT ARTICLE
Hepatitis C Virus-Induced Autophagy and Host Innate Immune Response.
Chan ST, Ou JJ.
Viruses
. 2017 Aug 12;9(8).
Paper

HCV plays with fire and yet avoids getting burned. A review for clinicians on processing bodies and stress granules.
Fernández-Carrillo C, Pérez-Vilaró G, Díez J, Pérez-Del-Pulgar S
Liver Int. 2017 A
 

Genetic variants underlying vitamin D metabolism and VDR-TGFβ-1-SMAD3 interaction may impact on HCV progression: a study based on dbGaP data from the HALT-C study.
de Azevedo LA, Matte U, da Silveira TR, Álvares-da-Silva MR.
J Hum Genet. 2017 Jul 13.
Abstract


Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
Grebely J, Bruneau J, Lazarus JV,  et al 
Int J Drug Policy. 2017 Jul 3.
Abstract

Changing trends in complications of chronic hepatitis C.
Lu M, Li J, Rupp LB,  et al 
Liver Int
. 2017 Jun 21.
Abstract

NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B
Morsica G, Andolina A, Merli M,  et al
Arch Virol. 2017 Apr
Abstract

Relationship between Hepatitis C Virus Infection and Iron Overload.
Zou DM, Sun WL.
Chin Med J (Engl). 2017 Apr 5;130(7):866-871.
Abstract

Hepatitis C virus infection.
Manns MP, Buti M, Gane E, et al
Nat Rev Dis Primers
. 2017 Mar 2;3:17006.
Abstract

Conflict of Interest in Seminal Hepatitis C Virus and Cholesterol Management Guidelines.
Jefferson AA, Pearson SD.
JAMA Intern Med. 2017 Jan 17
Abstract

Scaling-up HCV treatment to achieve WHO targets by 2030.
Cooke G.
Trop Med Int Health
. 2017 Jan 10.
Abstract

Genotype 3 Infection: The Last Stand of Hepatitis C Virus.
Chan A, Patel K, Naggie S
Drugs
. 2017 Jan 10.
Abstract

Intrahepatic angiopoietin-2 correlates with Chronic Hepatitis C progression and is induced in HCV replicon systems.
Hernández-Bartolomé Á, López-Rodríguez R,  et al
Liver Int. 2016 Dec 27.
Abstract
 

FULL-TEXT ARTICLE (link to download article)
Translation initiation by the hepatitis C virus IRES requires eIF1A and ribosomal complex remodeling.
Jaafar ZA, Oguro A, Nakamura Y, Kieft JS.
E
life
. 2016 Dec 23;
Paper

FULL-TEXT ARTICLE
Cynaropicrin: A Comprehensive Research Review and Therapeutic Potential As an Anti-Hepatitis C Virus Agent.
Elsebai MF, Mocan A, Atanasov AG.
Front Pharmacol. 2016 Dec 8;7:472
Paper

FULL-TEXT ARTICLE
Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C.
Schaefer EA, Meixiong J, Mark C, et al
World J Gastroenterol
. 2016 Dec 7;22(45):9954-9965. d
Paper

Hepatitis C genotype 3 disease.
Kattakuzhy S, Levy R, Rosenthal E, et al
Hepatol Int
. 2016 Nov;10(6):861-870.
Abstract

FULL-TEXT ARTICLE
Elevation of Alanine Aminotransferase Activity Occurs after Activation of the Cell-Death Signaling Initiated by Pattern-Recognition Receptors ‎but before Activation of Cytolytic Effectors in NK or CD8+ T Cells in the Liver During Acute HCV Infection.
Choi YH, Jin N, Kelly F, et al
PLoS One. 2016 Oct 27;11(10):e0165533.
Paper

Update on Hepatitis C treatment: Systematic review of clinical trials.
Jhaveri M, Procaccini N, Kowdley KV.
Minerva Gastroenterol Dietol. 2016 Oct 21.
Abstract

Innate immunity against hepatitis C virus.
Xu Y, Zhong J.
Curr Opin Immunol. 2016 Oct;42:98-104
Abstract

Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis.
Wijarnpreecha K, Thongprayoon C, Ungprasert P.
Eur J Gastroenterol Hepatol
. 2016 Sep 26
Abstract

Hepatitis C virus and human immunodeficiency virus transmission routes: Differences and similarities
Cainelli F.
World J Hepatol. 2013 May 27;5(5):234-6.
Abstract

FULL-TEXT ARTICLE
Hepatitis C virus, cholesterol and lipoproteins - impact for the viral life cycle and pathogenesis of liver disease
Felmlee DJ, Hafirassou ML, Lefevre M,  et al
Viruses
. 2013 May 23;5(5):1292-324.
Paper

Late autoimmune hepatitis after hepatitis C therapy.
Efe C, Heurgué-Berlot A, Ozaslan E,  et al
Eur J Gastroenterol Hepatol. 2013 Apr 26
Abstract

Patients with hepatitis C infection and normal liver function: an evaluation of cognitive function.
Abrantes J, Torres DS, de Mello CE.
Postgrad Med J. 2013 Apr 26.
Abstract

|A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care.
McGowan CE, Monis A, Bacon BR,  et al
Hepatology
. 2013 Jan 12.
Abstract

Pharmacogenomics of hepatitis C infections: personalizing therapy.
Booth DR, Ahlenstiel G, George J.
Genome Med. 2012 Dec 26;4(12):99.
Abstract

Vitamin A deficiency is associated with HCV chronic infection and with unresponsiveness to interferon based antiviral therapy.
Bitetto D, Bortolotti N, Falleti E, et al
Hepatology. 2012 Dec 5.
Abstract

HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.
Calle Serrano B, Manns MP
Antivir Ther. 2012;17(6 Pt B):1133-46
Abstract

Hepatitis C virus genotype 5: an orphan virus.
Antaki N, Abboud D, Antaki F, Craxi A.
Antivir Ther
. 2012 Oct 30.
Abstract

New perspectives in occult hepatitis C virus infection.
Carreńo V, Bartolomé J, Castillo I, Quiroga JA
World J Gastroenterol. 2012 Jun 21;18(23):2887-94.
Abstract

Fish to meat intake ratio and cooking oils are associated with hepatitis C virus carriers with persistently normal alanine aminotransferase levels.
Otsuka M, Uchida Y, Kawaguchi T, Taniguchi E, et al;
Hepatol Res. 2012 Mar 29.
Abstract
 

Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection.
Riviere Y, Montange T, Janvier G, Marnata C,  et al
Virol J
. 2012 Mar 28;9(1):76.
Abstract

Pharmacogenetics of hepatitis C.
Soriano V, Poveda E, Vispo E,  et al
J Antimicrob Chemother
. 2011 Dec 22
Abstract

Strong Correlation between Liver and Serum Levels of Hepatitis C Virus Core Antigen and RNA in Chronically Infected Patients.
Descamps V, Op de Beeck A, Plassart C, et al
J Clin Microbiol
. 2011 Dec 7.
Abstract

Demographics, socio-behavioral factors, and drug use patterns: What matters in spontaneous HCV clearance?
Shah DP, Grimes CZ, Brown E, Hwang LY.
J Med Virol
. 2012 Feb;84(2):235-41.
Abstract
 
Failure of innate and adaptive immune responses in controlling hepatitis C virus infection.
Thimme R, Binder M, Bartenschlager R.
FEMS Microbiol Rev. 2011 Dec 5. .
Abstract
 
Hepatitis C Virus Infects the Endothelial Cells of the Blood-Brain Barrier.
Fletcher NF, Wilson GK, Murray J, et al
Gastroenterology
.
2011 Nov 30.
Abstract

FULL-TEXT ARTICLE
Recombination in hepatitis C virus.
González-Candelas F, López-Labrador FX, Bracho MA.
Viruses
. 2011 Oct;3(10):2006-24.
Paper

FULL-TEXT ARTICLE
Clinical implications of chemokines in acute and chronic hepatitis C virus infection.
Kang W, Shin EC.
Yonsei Med J
. 2011 Nov 1;52(6):871-8.
Abstract

Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.
Grebely J, Pham ST, Matthews GV,  et al
Hepatology
. 2011 Oct 26.
Abstract
 
FULL-TEXT ARTICLE
Antibody V(h) Repertoire Differences between Resolving and Chronically Evolving Hepatitis C Virus Infections.
Racanelli V, Brunetti C, De Re V,  et al
PLoS One. 2011;6(9):e2560
Paper
 
All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C, McGarry LJ,  et al
J Manag Care Pharm
. 2011 Sep;17(7):531-46
Abstract
 
Low risk for hepatitis C seroconversion in methadone maintenance treatment.
Peles E, Schreiber S, Rados V, Adelson M.
J Addict Med
. 2011 Sep;5(3):214-20.
Abstract
 
Long-term follow-up among Danish transfusion recipients identified in the national hepatitis C lookback.
Just SA, Grau K, Georgsen J, et al
Transfusion
. 2011 Aug 29.
Abstract
 
Hot topic debate on HCV: The type of immunosuppression matters.
Trotter JF.
Liver Transpl. 2011 Aug 17
Abstract
 
Economic Burden Associated With Patients Diagnosed With Hepatitis C.
McCombs JS, Yuan Y, Shin J, Saab S.
Clin Ther. 2011 Aug 11.
Abstract

Vitamin A deficiency in patients with hepatitis C virus-related chronic liver disease.
Peres WA, Chaves GV, Gonçalves JC, Ramalho A, Coelho HS.
Br J Nutr
. 2011 Jun 8:1-8.
Abstract

 

Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis.
Jafari S, Copes R, Baharlou S, et al
Int J Infect Dis. 2010 Jul 31.
Abstract

 

 

 
 
    Videos
 
 
Polaris Symposium: Economic Impact of Eliminating HCV

 

Kirby Institute Symposium 2015 - Debate:
Global elimination of HCV is feasible in our lifetime

 


Pathogenesis
 
 

      Journal Papers, Abstracts, and Commentaries
 
 
The core of hepatitis C virus pathogenesis.
Kao CC, Yi G, Huang HC.
Curr Opin Virol. 2016 Feb 3;17:66-73.
Abstract

Virology and pathogenesis of hepatitis C virus recurrence.
Ramírez S, Pérez-Del-Pulgar S, Forns X.  
Liver Transpl. 2008 Oct;14 Suppl 2:S27-35.
Abstract

Pathogenesis of hepatitis C virus infection.
Kohla M, Bonacini M. et al 
Minerva Gastroenterol Dietol
. 2006 Jun;52(2):107-23
Abstract


Virology
 
 

      Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT ARTICLE
The Paradoxical Effects of Different Hepatitis C Viral Loads on Host DNA Damage and Repair Abilities.
Wang SC, Lai KR, Li CY,. et al
PLoS One. 2017 Jan 4;12(1):e0164281.
Paper

Consolidation of molecular testing in clinical virology.
Scagnolari C, Turriziani O, Monteleone K, Pierangeli A, Antonelli G.
Expert Rev Anti Infect Ther
. 2016 Dec 22
Abstract

Low Pretreatment Acoustic Radiation Force Impulse Imaging (ARFI) Values Predict Sustained Virological Response in Antiviral Hepatitis C Virus (HCV) Therapy.
Zopf S, Rösch L, Konturek PC, et al
Med Sci Monit. 2016 Sep 30;22:3500-3505.
Abstract

Role of HCV-RNA decay and IP-10 levels after 48hours of standard HCV therapy as predictors of rapid virological response.
Prinapori R, Sticchi L, Alicino C,  et al
Clin Res Hepatol Gastroenterol
. 2015
Abstract

Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis.
Cheng YL, Wang YC, Lan KH, et al
Ann Hepatol
. 2015 Mar-Apr 2015;14(2):181-189.
Abstract

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study.
Hajarizadeh B, Grady B, Page K, et al
J Viral Hepat
. 2015 Jan 8
Abstract

The association of il28b genotype with the histological features of chronic hepatitis C is HCV genotype dependent.
D'Ambrosio R, Aghemo A, De Francesco R, et al
Int J Mol Sci. 2014 Apr 25;15(5):7213-24
Abstract

FULL-TEXT ARTICLE
How hepatitis C virus invades hepatocytes: The mystery of viral entry.
Zhu YZ, Qian XJ, Zhao P, Qi ZT.
World J Gastroenterol
. 2014 Apr 7;20(13):3457-3467
Paper

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy.
Mauss S, Hueppe D, John C, et al
J Viral Hepat
. 2010 Sep 16.
Abstract

Sustained virological response according to the type of early virological response in HCV and HCV/HIV.
Lerias de Almeida PR, Alves de Mattos A, Valle Tovo C.

Ann Hepatol
. 2010 Jun 1;9(2):150-155.
Abstract


Natural History/Clinical Course
 
 

      Journal Papers, Abstracts, and Commentaries
 
 
Natural history and management of hepatitis C: does sex play a role?
Baden R, Rockstroh JK, Buti M.
J Infect Dis
. 2014 Jul 15;209 Suppl 3:S81-5.
Abstract

Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment.
Sagnelli E, Santantonio T, Coppola N,  et al
Infection
.
2014 Mar 12..
Abstract

Epidemiology and natural history of HCV infection.
Hajarizadeh B, Grebely J, Dore GJ.
Nat Rev Gastroenterol Hepatol. 2013 Jul
Abstract

Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up.
Nunnari G, Pinzone MR, Cacopardo B.
J Viral Hepat
. 2013 Apr;20(4):e131-7.
Abstract

 

Patient Perspectives
 
 

      Journal Papers, Abstracts, and Commentaries
 
 

A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
McEwan P, Selvapatt N, Brown A,  et al
Eur J Gastroenterol Hepatol. 2016 Nov 9. .
Abstract
 

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
Younossi ZM, Stepanova M, Henry L et al

Medicine (Baltimore). 2016 Jul;95(28):e4151

Abstract
 

FULL-TEXT ARTICLE
The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception.

Safo SA, Batchelder A, Peyser D, Litwin A. et al

Harm Reduct J. 2015 Jun 20;12(1):20
Paper
 

"Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment.

Batchelder AW, Peyser D, Nahvi S, et al

Drug Alcohol Depend. 2015 Jun 9.

Abstract

Physical, Social, and Psychological Consequences of Treatment for Hepatitis C : A Community-Based Evaluation of Patient-Reported Outcomes.
Manos MM, Ho CK, Murphy RC, Shvachko VA
Patient. 2013 Feb 1
Abstract


Vaccinations
 
 

      Journal Papers, Abstracts, and Commentaries
 
 
"Fitness for duty": Social, organisational and structural influences on the design and conduct of candidate hepatitis C vaccine trials involving people who inject drugs.
Treloar C, Byron P, McCann P, Maher L.
Vaccine
. 2010 Jun 7
Abstract

FULL-TEXT ARTICLE
Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: A review of the evidence and current recommendations.
Buxton JA, Kim JH.
Can J Infect Dis Med Microbiol. 2008 Mar;19(2):197-202
Paper


Links
 
 


Home Page Main New/Newsworthy  Disease Index      

 
 

Hepatitis C Main Page